Bitopertin (R enantiomer)Glycine reuptake inhibitor CAS# 845614-12-2 |
2D Structure
- Bitopertin
Catalog No.:BCC1419
CAS No.:845614-11-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 845614-12-2 | SDF | Download SDF |
PubChem ID | 46837366 | Appearance | Powder |
Formula | C21H20F7N3O4S | M.Wt | 543.46 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | RG1678 (R enantiomer); RO4917838 (R enantiomer) | ||
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2R)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone | ||
SMILES | CC(C(F)(F)F)OC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)N2CCN(CC2)C3=C(C=C(C=N3)C(F)(F)F)F | ||
Standard InChIKey | YUUGYIUSCYNSQR-GFCCVEGCSA-N | ||
Standard InChI | InChI=1S/C21H20F7N3O4S/c1-12(20(23,24)25)35-17-4-3-14(36(2,33)34)10-15(17)19(32)31-7-5-30(6-8-31)18-16(22)9-13(11-29-18)21(26,27)28/h3-4,9-12H,5-8H2,1-2H3/t12-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Bitopertin is a potent, noncompetitive glycine reuptake inhibitor, inhibits glycine uptake at human GlyT1 with a concentration exhibiting IC50 of 25 nM.In Vitro:Bitopertin (RG1678) competitively blocks [3H]ORG24598 binding sites at human GlyT1b in membranes from Chinese hamster ovary cells. Bitopertin potently inhibits [3H]glycine uptake in cells stably expressing hGlyT1b and mGlyT1b, with IC50 values of 25±2 nM and 22±5 nM, respectively (n=6). Conversely, Bitopertin has no effect on hGlyT2-mediated glycine uptake up to 30 μM concentration. Bitopertin has high affinity for the recombinant hGlyT1b transporter. Under equilibrium conditions (1 h at room temperature), Bitopertin displaces [3H]ORG24598 binding with a Ki of 8.1 nM. In hippocampal CA1 pyramidal cells, Bitopertin enhances NMDA-dependent long-term potentiation at 100 nM but not at 300 nM[1]. Additional profiling revealed that Bitopertin (RG1678) has an excellent selectivity profile against the GlyT2 isoform (IC50>30 μM) and toward a panel of 86 targets including transmembrane and soluble receptors, enzymes, ion channels, and monoamine transporters (<41% inhibition at 10 μM is measured for all targets)[2].In Vivo:Bitopertin (RG1678) dose-dependently increases cerebrospinal fluid and striatal levels of glycine measured bymicrodialysis in rats. Additionally Bitopertin attenuates hyperlocomotion induced by the psychostimulant D-amphetamine or the NMDA receptor glycine site antagonist L-687,414 in mice. Bitopertin also prevents the hyper-response to D-amphetamine challenge in rats treated chronically with phencyclidine, an NMDA receptor open-channel blocker. Administration of vehicle has no effect on extracellular levels of striatal glycine, which remained constant throughout the experiment. In contrast, p.o. administration of Bitopertin (1-30 mg/kg) produced a dose-dependent increase in extracellular glycine levels. Bitopertin 30 mg/kg produces glycine levels 2.5 times higher than pretreatment levels. A similar dose-dependent increase in glycine concentration is observed in the CSF of rats treated p.o. with Bitopertin (1-10 mg/kg) compared with vehicle-treated animals, 3 h after drug administration. Interestingly, the level of CSF glycine increase 3 h after Bitopertin dosing is very similar to the increase in the microdialysis experiment at the same time point[1]. In vivo pharmacokinetic studies in rat and monkey reveals that Bitopertin (RG1678) has, in both species, a low plasma clearance, an intermediate volume of distribution, a good oral bioavailability (78% for rat, 56% for monkey), and a favorable terminal half-life (5.8 h for rat, 6.4 h for monkey). The plasma protein binding is high in the two preclinical species (97%) and in human (98%). The CNS penetration of Bitopertin in rat (brain/plasma=0.7) is better than that in mouse (brain/plasma=0.5)[2]. References: |
Bitopertin (R enantiomer) Dilution Calculator
Bitopertin (R enantiomer) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.8401 mL | 9.2003 mL | 18.4006 mL | 36.8012 mL | 46.0015 mL |
5 mM | 0.368 mL | 1.8401 mL | 3.6801 mL | 7.3602 mL | 9.2003 mL |
10 mM | 0.184 mL | 0.92 mL | 1.8401 mL | 3.6801 mL | 4.6002 mL |
50 mM | 0.0368 mL | 0.184 mL | 0.368 mL | 0.736 mL | 0.92 mL |
100 mM | 0.0184 mL | 0.092 mL | 0.184 mL | 0.368 mL | 0.46 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
R enantiomer of RG1678. RG1678 (Bitopertin) is a potent and noncompetitive glycine reuptake inhibitor (GlyT1). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics. RG1678 is currently in Phase III trials for the treatment of the negative symptoms of schizophrenia.
- Bitopertin
Catalog No.:BCC1419
CAS No.:845614-11-1
- MNI-caged-D-aspartate
Catalog No.:BCC5896
CAS No.:845555-94-4
- Bedaquiline fumarate
Catalog No.:BCC5245
CAS No.:845533-86-0
- ICI 162,846
Catalog No.:BCC6808
CAS No.:84545-30-2
- Sevelamer Carbonate
Catalog No.:BCC4717
CAS No.:845273-93-0
- Varlitinib (ARRY334543)
Catalog No.:BCC3725
CAS No.:845272-21-1
- Sibutramine hydrochloride
Catalog No.:BCC5252
CAS No.:84485-00-7
- BTS 54-505 hydrochloride
Catalog No.:BCC5901
CAS No.:84484-78-6
- C-1
Catalog No.:BCC6687
CAS No.:84468-24-6
- threo-Guaiacylglycerol-beta-O-4'-dehydrodisinapyl ether
Catalog No.:BCN6928
CAS No.:844637-85-0
- β-CCB
Catalog No.:BCC6635
CAS No.:84454-35-3
- A-769662
Catalog No.:BCC2080
CAS No.:844499-71-4
- 4-Hydroxycephalotaxine
Catalog No.:BCN4386
CAS No.:84567-08-8
- PHA-767491
Catalog No.:BCC1858
CAS No.:845714-00-3
- Rocaglamide
Catalog No.:BCN4387
CAS No.:84573-16-0
- Cleomiscosin C
Catalog No.:BCN4388
CAS No.:84575-10-0
- Bakuchalcone
Catalog No.:BCN3201
CAS No.:84575-13-3
- CP 94253 hydrochloride
Catalog No.:BCC7018
CAS No.:845861-39-4
- 2-Methyl-5-hydroxytryptamine hydrochloride
Catalog No.:BCC5663
CAS No.:845861-49-6
- Serrin A
Catalog No.:BCN6985
CAS No.:845959-98-0
- 5α-Androstanedione
Catalog No.:BCC8752
CAS No.:846-46-8
- Boldenone
Catalog No.:BCC8892
CAS No.:846-48-0
- Lorazepam
Catalog No.:BCC5970
CAS No.:846-49-1
- Cyclogalegigenin
Catalog No.:BCN6295
CAS No.:84605-18-5